Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer
- PMID: 32111601
- DOI: 10.1158/2159-8290.CD-RW2020-030
Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer
Abstract
The anti-HER2-drug conjugate trastuzumab deruxtecan (T-DXd) was effective in HER2-low breast cancer.
©2020 American Association for Cancer Research.
Comment on
-
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058843 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous